ADVA
7.6.2021 09:09:59 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that its FSP 3000 open line system (OLS) and Ensemble Controller network management and SDN domain controller system played a key role in a successful Telecom Infra Project (TIP) open optical networking proof of concept (PoC). The demo is a crucial step for vendor-neutral disaggregated solutions with operators able to mix and match best-in-breed technology and leverage different product lifecycles. The PoC showed how multi-vendor network components can be managed by a unified software-defined networking (SDN) control system. Specifically designed for easy interoperability, ADVA’s FSP 3000 OLS and Ensemble Controller ensured seamless integration into the open environment, including third-party terminals. The PoC will be on display at OFC at the virtual Demo Zone from June 7 to 11.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210607005193/en/
“This PoC is an important milestone in the journey to fully open and disaggregated optical networking. It offers new levels of visibility and a way to manage the entire multi-vendor environment. With the power to seamlessly integrate components from different suppliers, network operators can confidently deploy best-in-class infrastructure that meets their exact requirements,” said Christoph Glingener, CTO, ADVA. “Our FSP 3000 OLS was central to the demo. It’s a truly open solution that gives operators freedom to build multi-supplier architectures and then evolve and optimize each network layer separately. With our Ensemble Controller also playing a major role – providing network management and programmatic SDN control – this demo highlights the value of technology like ours that supports interoperability and disaggregation.”
Conducted by TIP’s Converged Architectures for Network Disaggregation & Integration (CANDI) sub-group, the PoC proved that all components of an open optical network can be operated by a single SDN controller. By demonstrating unified management of the OLS, open terminals and optical planning tool, the demo paves the way for true open networking and a new model of infrastructure operations with operators taking over network integration and optimization processes. The demo utilized ADVA’s compact and modular FSP 3000 OLS. With its open interfaces, the OLS interworks seamlessly with third-party transceivers and supports the latest coherent transport innovation. It also featured ADVA’s Ensemble Controller network management system, which was specifically designed to help network operators break up network layers while moving towards a software-defined multi-vendor architecture. TIP partners collaborating with ADVA on the demo included the major network operators Orange, Telefónica and Telia Company.
“The success of TIP’s PoC offers a major boost to communication service providers looking to harness the benefits of increased agility and supplier diversity in their optical infrastructure. Our open technology gives network operators the opportunity to massively increase efficiencies by moving away from closed proprietary systems and towards vendor-neutral networking,” commented Stephan Neidlinger, VP, global business development, ADVA. “The TIP community has once again accomplished a significant step forward for open, disaggregated and standards-based connectivity technology. By collaborating closely with our partners in this project, our team has helped to accelerate the development of the next generation of communication networks, free from vendor lock-in and ready to connect tomorrow’s world.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20210607005193/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom